Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Patient-Reported “Good” Days During a Prospective Study of the Treatment of Neurogenic Orthostatic Hypotension With Droxidopa
Movement Disorders
P14 - Poster Session 14 (8:00 AM-9:00 AM)
3-016
To evaluate the effect of droxidopa treatment on patient-reported assessments of a “good” or “bad” day in patients with nOH
Droxidopa is approved in the United States to treat symptomatic neurogenic orthostatic hypotension (nOH) in adults. Common symptoms of nOH include lightheadedness and dizziness, which can lead to an increased likelihood of falls. Patients with nOH may experience decreased functional ability and an increased fear of falling, which can cause feelings of depression and anxiety, leading to social isolation.
In a 6-month prospective cohort study of patients with nOH newly initiating droxidopa treatment, participants were asked to quantify the number of good and bad days in the past week. Participants also reported outcomes using other validated instruments that measure nOH symptoms (Orthostatic Hypotension Symptom Assessment Item 1), functional impairment (Sheehan Disability Scale), depressive symptoms (Patient Health Questionnaire-9), fear of falling (Falls Efficacy Scale-International), and health-related quality of life (HRQoL; Short Form-8). Scores after 1 and 6 months of treatment were compared with baseline.
After 1 month of droxidopa treatment, patients reported a significant increase in good days from baseline (mean, 4.2 vs 3.3 days/week; difference, 0.9 days/week; P<0.0001). Similar positive effects for the increase in reported good days were observed at 6 months vs baseline (mean, 4.5 vs 3.4 days/week; difference, 1.1 days/week; P<0.0001). The significant increase in good days at 1 and 6 months correlated with improvements in other patient-reported outcomes of nOH symptoms, fear of falling, functional impairment, depressive symptoms, and HRQoL (all P<0.0001).
Patients treated with droxidopa reported significantly more good days per week compared with before treatment initiation. The increased number of good days tracked with improvements in other patient-reported indicators of mental wellbeing. Improved patient perception of psychological status may represent an important downstream holistic benefit of nOH treatment.
Authors/Disclosures
Steven Kymes
PRESENTER 		Steven Kymes has received personal compensation for serving as an employee of Lundbeck. Steven Kymes has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Ophthalmology. Steven Kymes has received research support from Emmes Corporation.
Lawrence Hewitt (Lundbeck) Lawrence Hewitt has received personal compensation for serving as an employee of Lundbeck.
Clement Francois No disclosure on file